Preceptorship Programme

23rd May to 25th May 2022

7:30 pm to 10:00 pm (SGT)

Preceptorship Programme

23rd May to 25th May 2022

7:30 pm to 10:00 pm (SGT)

The Preceptorship Programme is designed to enhance the knowledge of  junior faculty, young doctors, trainers and new specialists with up-to-date clinical guidance. This year, using Evidence Based Medicine as a foundation of learning, the Trainers will continue to focus on this objective of improving and updating young doctors on new techniques in treating common liver conditions.  We will discuss complex liver cases to exemplify and obtain insights into their management.

To facilitate interactions between the Trainers and all our Preceptees, each Preceptee is required to submit a difficult case study on HBV, HCV, NASH, HCC or other liver disease.  Of these, 9 to 10 cases studies were selected for oral presentations on line and the Preceptees will be awarded a prize of US$200.  Each evening, the Preceptee with the top Case Presentation will be awarded the a prize worth US$1,000.

Please click on "WATCH VIDEO" below to view the videos of the Experts Presentations and the Case Study Presentations.

All Preceptees who submitted a Case Study to the Preceptorship Programme 2022 will be given favourable consideration to attend the Preceptorship Programme and/or the Singapore Hepatology Conference when it can be held LIVE in Singapore.

CASE SUBMISSIONS ARE NOW CLOSED

But YOU can still participate in the Preceptorship Programme 2022 and listen to expert hepatologists from National University Hospital, Singapore explain the structured approach for diagnosing and treating liver diseases

REGISTER FOR PRECEPTORSHIP PROGRAMME

Benefits

The following benefits are available to Young Doctors who have been accepted for the Preceptorship Programme Online

What will you learn?

In this Preceptorship Programme you will learn:

  • The latest updates and training for the clinical management of liver diseases including Chronic Hepatitis B and C, NASH, HCC and other liver diseases
  • The natural history of Hepatitis B and C, NASH and HCC
  • How to interpret clinical data and manage complex liver disease cases.

Eligibility

The applicant must:

  • Have a Medical Degree in their country and be a practicing physician or trainee
  • Be considered a Junior Doctor (below Assistant Professor), Trainee, Recent Specialist or Physician
  • Submit a difficult case study on HBV, HCV, NASH or HCC
  • Junior Doctors must not be resident in Singapore to be eligible to participate in the Preceptorship Programme Online

Awards

Preceptees who submit Case Studies to the Preceptorship Programme 2022 will be given favourable consideration to attend the Preceptorship Programme when held LIVE in Singapore.

Preceptees whose Case Studies have been selected for oral presentations will be awarded a sum of USD 200.
Preceptees whose Case Studies have been ranked in the top three oral presentations will be awarded a sum of USD 1,000.00.

Awards payments shall only be made on the following terms and conditions:

  1. One person, one application only.
  2. The preceptee’s attendance of at least 80% of the Preceptorship Programme and Online Conference is verified by SHC’s electronic records.
  3. If the young doctor’s case study is accepted for oral presentation, he/she must present his/her case at the online webinar.
  4. Payments will be made By Bank Transfer to the Presenters’ account and the USD amount may be converted to local currency as required by the in country authorities.

Application Procedure

Important Dates

February

10

Preceptorship Programme - Applications Open

May

8

Preceptorship Programme - Applications Close

May

14

Notification of Acceptance & of Oral Presentation

May

23 May – 25 May

Attend Preceptorship Programme

Digital Preceptorship Programme 2022

May, 2022

23

Programme Time (SGT)
Evidence Based Medicine (EBM) and interpretation of the medical literature
Prof. Seng Gee Lim (Singapore) View Bio
19:30 – 20:15
Investigation of abnormal LFTs Prof. Yock Young Dan View Bio 20:15 – 20:45
Q & A 20:45 – 21:00
Case Presentations (1 hour) 21:00 – 22:00

May, 2022

24

Programme Time (SGT)
Benign liver diseases and how to diagnose them: fibrosing nodular hyperplasia, hemangioma, hepatic adenomas and hepatic cysts Dr. Prem H Thurairajah View Bio 19:30 – 20:15
Is cirrhosis present? Diagnosis of cirrhosis, non invasive markers and when to biopsy Dr. Guan Huei Lee View Bio 20:15 – 20:45
Q & A 20:45 – 21:00
Case Presentations (1 hour) 21:00 – 22:00

May, 2022

25

Programme Time (SGT)
Progression of liver disease from cirrhosis to decompensation Dr. Mark Muthiah View Bio 19:30 – 20:15
Overview of biliary diseases Dr. Calvin Koh View Bio 20:15 – 20:45
Q & A 20:45 – 21:00
Case Presentations (1 hour) 21:00 – 22:00

Dr. Calvin Koh

Dr Koh Jianyi, Calvin obtained his medical degree (MBBS) from the National University of Singapore and underwent further medical training at the National University Hospital, Singapore, in the division of gastroenterology and hepatology, completing his Advanced Specialist Training in gastroenterology.

Following completion of specialist training, he was awarded an Academic Medicine Development Award and undertook an advanced endoscopy fellowship under the auspices of the American Society for Gastrointestinal Endoscopy with the Division of Gastroenterology, Hepatology and Nutrition at the University of Florida, USA to further his interest in interventional endoscopy.

Dr Koh is currently a Consultant at the Division of Gastroenterology and Hepatology, as well as an Assistant Professor at NUS Yong Loo Lin School of Medicine. He currently serves as the director of the Endoscopy Centre, at National University Hospital, Singapore, as well as a core faculty member for the gastroenterology training program. He is a fellow of the Royal College of Physicians (London), as well as the American Society of Gastrointestinal Endoscopy.

His clinical and research interests are pancreatobiliary disease, gastric cancer, colon cancer and general gastroenterology/hepatology. Besides gastroscopy and colonoscopy, he also performs endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, endoscopic mucosal resection of polyps, small bowel enteroscopy.

Dr. Arun Sanyal

Arun J. Sanyal, M.D., is the interim Chair of the Department of Gastroenterology, Hepatology and Nutrition and Professor of Medicine, Physiology and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia. Dr. Sanyal has recently been named Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. Dr. Sanyal also serves as Chairman of the NIH NASH Clinical Research Network, the NIMBLE consortium and the Liver Forum for NASH and fibrosis. His research interests include all aspects of NAFLD and NASH as well as complications of cirrhosis and end stage liver disease. He has been continuously funded by the NIH since 1995 and has over 350 peer reviewed publications with a H-index of 116. He was also recently ranked in top 0.01% of medical scientists based on their impact on the field (PlosBio 2019). He has served in several leadership roles nationally and globally including Chair of the Hepatobiliary Pathophysiology Study Section of the NIH, Secretary and then President of the American Association for Study of Liver Disease, founding member of the American Board of Internal Medicine Transplant Hepatology board examination and member of WHO advisory council on viral hepatitis. He is the co-founder and academic chair of the Liver Forum which is a platform to bring regulatory agencies (FDA and EMA) with industry and academics to accelerate drug development for NASH and advanced liver disease. He is currently engaged in numerous clinical trials and leads several phase 2B and 3 trials for NASH as well as complications of end stage liver disease. His contributions have been recognized by receiving the Distinguished Mentorship Award from the American Gastroenterological Association and the Distinguished Scientific Achievement Award from the American Liver Foundation in 2017 and the Distinguished Achievement Award from the AASLD in 2018.

Dr. Prof. Ed Gane

Prof. Ed Gane, MBCHB, MD, FRACP, FRSNZ, FAASLD, MNZM
New Zealand Liver Transplant Unit
Auckland City Hospital, New Zealand

Dr. Gane is Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital.
Dr. Gane trained in hepatology at the Institute of Liver Studies, King’s College School of Medicine, London, where he completed his MD on the pathogenesis of hepatitis C-related liver injury. Dr Gane chairs the Ministry of Health committee responsible for HCV elimination and co-wrote the first New Zealand National HepC Action Plan.
Dr. Gane is an investigator for many international clinical trials with particular interest in early phase development of new direct acting antiviral therapies against chronic hepatitis C, hepatitis B, NASH and HCC. He has published over 600 papers in peer-reviewed journals including The Lancet and The New England Journal of Medicine. Dr Gane is a member of APASL, EASL, ILTS, ILCA and AASLD and is an Associate Editor for the Journal of Hepatology
In 2011, Dr Gane received the New Zealand Health Research Council (NZHRC) annual Beaven Medal and in 2014, the NZHRC annual Liley Medal.
In 2011, Dr. Gane was awarded Member of the Order of New Zealand for Services to Medicine.
In 2017, Dr Gane was named as New Zealand Innovator of the Year for his work towards HCV elimination in New Zealand.
In 2018, he was elected to the Royal Society of Medicine.

Prof. Pierce Chow

Pierce Chow is Professor and Program Director at the Duke-NUS Medical School and Senior Consultant Surgeon at the National Cancer Centre Singapore (NCCS) and the Singapore General Hospital. He is concurrently a National Medical Research Council (NMRC) funded Senior Clinician-Scientist and was the founding President of the College of Clinician Scientists, Academy of Medicine Singapore. Prof Chow was conferred the Chapter of Surgeon’s Gold Medal in the conjoint FRCSE/MMed examination in 1995, and after completing his surgical residency and PhD, he trained in liver transplantation with Professor Russell Strong in Australia. Pierce leads the multi-disciplinary NMRC TCR National Flagship Program in Liver Cancer. In 2020, he was awarded an A*STAR IAF-ICP grant to conduct a nation-wide 2000-patient cohort study to develop diagnostics for early detection of hepatocellular carcinoma in high-risk patients. Pierce is also a faculty member at the Genome Institute of Singapore, the SingHealth Duke-NUS Global Health Institute and Research Director at the Institute of Cell and Molecular Biology Singapore. Prof Chow was conferred the NMRC National Outstanding Clinician Scientist Award in 2012 for improving clinical outcomes with his research on Liver Cancer.

Prof. Yock Young Dan

Prof. Yock Young Dan
MBBS (S’pore), Ph.D, MMed (Int Med), MRCP (UK), FAMS (Gastroenterology) Head, Dept. of Medicine, NUH
Head and A/ Professor, Dept. of Medicine, NUS Adjunct, Cancer Science Institute
Associate Faculty, GIS Partnership Programme, Genome Institute of Singapore
Senior Consultant, Div. of Gastroenterology & Hepatology, Dept. of Medicine, NUH
Senior Consultant, Liver Transplantation, National University Centre for Organ Transplantation, NUH
Dr Dan Yock Young obtained his basic medical degree (MBBS) from the National University of Singapore in 1994. He went on to complete his basic specialty training and obtained a Master of Internal Medicine (MMED S’pore) and membership of the Royal Colleges of Physicians of the UK, MRCP (UK) in 1998. He obtained his Gastroenterology fellowship from the Academy of Medicine, Singapore (FAMS S’pore) in 2003. From 2003 to 2005, Dr Dan was awarded the A*STAR International Fellowship and he spent 2 years at the University of Washington researching liver stem cells and liver regeneration. This work subsequently led to him being awarded a PhD from NUS in 2010.

He has vast clinical interests in hepatology which includes viral hepatitis B and C, liver transplantation and liver cirrhosis. He is a clinician scientist and his interests include the cost-effectiveness of clinical treatments, liver progenitor cells and their therapeutic applications, as well as pathogenesis and treatment targets in liver failure.

Dr. Thomas Tu

Dr. Thomas Tu is a molecular biologist with a particular focus on integrated Hepatitis B virus DNA and its role in disease progression. He currently leads a research group at the Westmead Institute for Medical Research in the Storr Liver Centre (Sydney, Australia), where his team focuses on persistent forms of the Hepatitis B virus (covalently closed circular DNA and integrated HBV DNA). He is particularly passionate about developing a HBV cure and mitigating the associated liver cancer, as he himself lives with chronic Hepatitis B.
Dr. Tu is currently President of the Australian Centre for Hepatitis Virology (ACHV), the premier Australian society for hepatitis virus researchers. He is also board member of Hepatitis Australia, guiding the strategic direction of the peak national advocacy body for people with liver disease. Finally, Dr. Tu is founder and Executive Director of HepBCommunity.org (a global support network for people affected with HBV), guiding people through their HBV diagnosis and linking them with trustworthy scientific and medical information.

Prof. Vincent Wong

MBChB (Hons), MD (CUHK), FRCP (Edin), FHKCP, FHKAM (Medicine)
Professor, Dept. of Medicine & Therapeutics Head, Div. of Gastroenterology and Hepatology
Director, Cheng Suen Man Shook Centre for Hepatitis Research Deputy Director, Center for Liver Health
Faculty of Medicine, The Chinese University of Hong Kong Honorary Consultant, Prince of Wales Hospital, Hospital Authority
Vincent Wong, MD, is a Professor in the Department of Medicine and Therapeutics at the Chinese University of Hong Kong, where he undertakes research on aspects of viral hepatitis and
non-alcoholic fatty liver disease (NAFLD). Along with authoring over 350 articles in international medical journals, Prof. Wong is a pioneer in the development of hepatocellular carcinoma prediction scores and has performed important validation studies on the non-invasive assessment of NAFLD by transient elastography.

Prof. Lim Seng Gee

Qualifications:
MBBS (Hons Monash), FRACP (Aust), FRCP (London), MD (Monash), FAMS (S’pore), Cert Immunology (King’s College)

Biosketch
Prof Lim currently serves as a Senior Consultant at the Division of Gastroenterology and Hepatology in the National University Hospital, Singapore. He is also a Professor in the Yong Loo Lin School of Medicine, National University of Singapore.  

Prof Lim attained his basic medical degree with honours (MBBS Hons) from the University of Monash, Melbourne, Australia. He later pursued a doctorate degree (MD) in Monash and was awarded the FRACP (Australia), FRCP (London), FAMS (Gasteroenterology, Singapore).  

He is considered a master clinician having trained over 40 gastroenterologists and hepatologists, and is regularly referred difficult to treat liver cases. His main clinical work focuses on the treatment of viral hepatitis (esp. B and C), liver disease and liver cancer. 

Prof Lim’s research activities include leadership in Hepatology research, which focuses on improving treatment for chronic hepatitis B and C, pathophysiology of hepatitis B disease, HBV virology, immunological mechanisms of HBeAg seroconversion, and loss of immune tolerance to hepatitis B virus. He also has an interest in pathophysiology and treatment of liver cancer, primary hepatocyte culture, hepatocyte function, drug related liver disease and non-alcoholic fatty liver disease. 

Prof Lim has over 253 publications in peer-reviewed journals with a H-index of 51, and sits on the editorial board of Liver International Hepatology, International, J Viral Hepatitis, Alimentary Pharmacology and Therapeutics, and Lancet Gastroenterology and Hepatology. He has received over S$48 million in research grants.  

Prof Lim also sits on the Advisory Board of Novartis Pharmaceuticals, Idenix Pharmaceuticals, Bristol Myers Squibb Pharmaceuticals and is on the Speaker’s Bureau for GlaxoSmithKline and Schering Plough Pharmaceuticals. Prof Lim has been an invited speaker at AASLD, EASL and APASL in 2013, 2014 and is a regular speaker at numerous International and Regional meetings on liver disease and viral hepatitis. 

Prof Lim is also an Evidence Based Medicine (EBM) Champion, having founded the annual Asia Pacific EBM workshop in 2004 together with Prof Tony Dans from the Philippines which still runs yearly, and actively teaches and contributes to the development of EBM in Singapore.

Prof Lim is Council member, International Coaliltion for Eradication of Hepatitis B Virus (ICE-HBV), AASLD Asia Pacific Regional Council member, Co-chair ICE-HBV treatment subcommittee, and Co-chair combination therapy subcommittee HBV Forum.

Dr. Guan Huei Lee

Designations:

  • Senior Consultant, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital
  • Senior Consultant, Liver Transplantation, National University Centre for Organ Transplantation, National University Hospital
  • Medical Director, Adult Liver Transplantation Programme, National University Centre for Organ Transplantation, NUH
  • Research Director, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital

Qualifications:
MBBS (S’pore), MRCP (UK), FRCP Ed (UK), Ph.D. (S’pore)

Specialties:
Medicine, Organ Transplantation

Sub-specialties:
Gastroenterology Hepatology, Liver Transplantation

Special Interests:
Viral hepatitis, Liver failure, Liver transplantation, Liver cirrhosis, Fatty liver disease.

Biosketch
Dr. Guan-Huei Lee graduated from the National University of Singapore (NUS), and completed his advance specialist training in Gastroenterology in 2009. He received further training a clinical fellow at the Institute of Liver Studies, King’s College Hospital, London, focusing on liver intensive care. He received his PhD from NUS in 2014. He was awarded Fellowship of the Royal College of Physicians of Edinburgh in 2015.

Dr. Lee has helped to strengthen the clinical and research capabilities of the Division of Gastroenterology & Hepatology, National University Hospital (NUH), particularly in the management of liver failure and liver transplantation. He is serving dual role as Deputy Head, Division of Gastroenterology & Hepatology, and Medical Director, Adult Liver Transplantation Programme, National University Centre for Organ Transplantation (NUCOT).

Dr. Lee’s research work centers on the application of innovations in technology and biomedical science to the field of Hepatology.  His current work focuses on developing novel targets to achieve functional cure of chronic hepatitis B. His other research interest includes liver failure, liver cancer, fatty liver and chronic hepatitis E. He has published multiple peer-reviewed research articles in such top-tier journals as the Gastroenterology, Gut, and Molecular & Cellular Biology. His research work has been presented at the major meetings of such organisations as the APASL, EASL, ILTS, and AASLD. He is an investigator of several competitive research grants including the Translational & Clinical Research Flagship (TCR) Programme grant, Clinician Scientist-Individual Research Grant (CS-IRG) and was awarded the NMRC Clinician Scientist Award (CSA).

Personal hobbies and interests: Reading, Tennis, Photography, Hiking and Mountain Climbing.

Dr. Daniel Huang

Qualifications:
MBBS (S’pore), MMED (Int Med)(S’pore), MRCP (UK)

Biosketch
Dr Daniel Huang graduated from the Yong Loo Lin School of Medicine, National University of Singapore, and did his postgraduate residency training in NUH. He completed his fellowship in Gastroenterology and Hepatology, and was certified by the Specialist Accreditation Board of Singapore.

Dr Huang has a keen interest in liver transplantation, and is a member of the liver transplant team at the National University Hospital, Singapore. He is also proficient in diagnostic and therapeutic endoscopy.

Dr Huang’s research interest is in hepatocellular carcinoma oncogenesis in the setting of NAFLD and hepatitis B, and performs translational and clinical research in these areas.

Area of Interest:

  • Hepatocellular carcinoma
  • Liver transplantation
  • Non-alcoholic fatty liver disease
  • Hepatitis B

Dr. Mark Muthiah

Qualifications:
MBBS (S’pore), MRCP (UK), M.Med (Int Med, S’pore).

Biosketch
Dr Mark Muthiah is a Consultant specialising in Gastroenterology and Hepatology at the National University Hospital, Singapore. He graduated from the Yong Loo Lin School of Medicine, National University of Singapore, and did his postgraduate residency training in NUH. He completed his fellowship in Gastroenterology and Hepatology, and was certified by the Specialist Accreditation Board of Singapore in 2016. 

Dr Muthiah has a keen interest in liver transplants, and is a member of the liver transplant team at the National University Hospital, Singapore. He is also skilled in diagnostic and therapeutic endoscopy, and is involved in colon cancer screening and endoscopic mucosal resection (EMR) of colon polyps. 

Dr Muthiah’s research interest is in cellular therapies to reverse liver fibrosis and promote liver regeneration, and is actively involved in basic and translational research on this subject. He is also the principal investigator for ongoing studies in the field of liver cirrhosis and liver transplantation. He has received awards for his research at both regional and international conferences. 

Dr Muthiah is actively involved in medical education for undergraduates, postgraduates, dentistry students, and pharmacy students. He has received numerous teaching awards from NUH, as well as the Outstanding Tutor Award from the Medical Student Society at the Yong Loo Lin School of Medicine. 

Dr. Prem H Thurairajah

Qualifications:
MBBS (India), MRCP (UK), PhD (UK)

Biosketch
Dr. Thurairajah graduated from Kasturba Medical College in India in 1997. He subsequently pursued training in Internal Medicine in the United Kingdom which culminated with membership to the Royal College of Physicians (MRCP) in 2002. He trained in Gastroenterology and Hepatology at the West Midlands Deanery, Birmingham, UK and completed two fellowship stints, his first in Transplant Hepatology at the Liver Unit at Queen Elizabeth Hospital in Birmingham and his second in Hepatobiliary endoscopy (ERCP and EUS) at the University College of London (UCL) before obtained his Completion of Certificate in Specialist Training (CCST) in 2011. He completed a period of research leading to a Doctorate in Philosophy (PhD) in the field of Hepatitis C in 2010. He is well published in peer reviewed journals and continues to engage in clinical research.

He worked as a Consultant Transplant Hepatologist at St. James University Hospital, Leeds, UK in 2012 before moving to the Liver Transplant Unit at the University of Kentucky, USA  as an Assistant Professor in Medicine where he served for 2 years. He moved to Singapore in 2014 and worked at Changi General Hospital , where he set up a treatment programme for Chronic Hepatitis C and served as the Director of Hepatology.

Dr. Chee Cheng Ean

Dr. Chee Cheng Ean is a Senior Consultant in Medical Oncology and Deputy Director (Clinical) at the National University Cancer Institute, Singapore (NCIS). She is also Assistant Professor of Medicine, Yong Loo Lin School of Medicine, NUS. Dr Chee’s interests are in GI cancers (colorectal, liver and pancreas cancers), drug development of novel agents, phase I trials and cancer survivorship.

Prof. Rohit Loomba

Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic steatohepatitis (NASH), and non-invasive assessment of NAFLD using advanced imaging modalities.

Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 50 clinical trials conducted worldwide. He holds a patent on non-invasive biomarkers of NASH and fibrosis.

His research is funded by the National Institutes of Health including three R01s, three U01 (two NIDDK and one from NIAAA), core director of P30 (NIDDK) and project director P01 (NHLBI) grant mechanisms, Foundation of NIH, National Science Foundation as well as several investigator initiated research projects funded by the industry. He is the Principal Investigator, UCSD, for the NIDDK-sponsored NASH Clinical Research Network. He served as the elected Chair of the NAFLD, Special Interest Group of the American Association for the Study of Liver Diseases. And is the elected member to the National Board of Directors of the American Liver Foundation.

He serves on the Editorial Board of Gastroenterology, Journal of Hepatology, GUT and Nature Reviews in Gastroenterology and Hepatology. He recently completed a 5-year term as the Deputy Editor of HEPATOLOGY, the official journal of the AASLD. Currently, he serves as the co-Editor of Alimentary Pharmacology and Therapeutics, an international journal in the field of gastroenterology and Hepatology.

Dr. Loomba has published more than 350 manuscripts and has an H-index of 99. He is among the top 1% of the globally highly cited scientists across all fields in 2019, 2020 and 2021 by Web of Science. He is an elected member of American Society of Clinical Investigation.

Prof. Man Fung Yuen

MD, PhD, DSc

Professor Yuen is now the Chair and Chief of the Division of Gastroenterology and Hepatology in the University of Hong Kong. He obtained his first bachelor degree of medicine in 1992. He further pursued his academic excellence through the achievement of obtaining 3 doctoral degrees including Doctor of Medicine with Sir Patrick Manson Gold Medal in 2001, Doctor of Philosophy in 2005 and Doctor of Science in 2017.

Professor Yuen’s research interests include prevention, natural history, serology, virology and treatment of chronic hepatitis B and C, and hepatocellular carcinoma. He is one of the top internationally renowned researchers in the field of hepatitis B disease. He has now published more than 490 papers in world renowned medical journals including New England Journal of Medicine, Lancet, Nature Medicine, Lancet Infectious Diseases, Lancet Oncology.

As a world-class clinician scientist, Professor Yuen is now leading most of the international trials examining new drugs including antiviral and immunomodulatory agents for the treatment of chronic hepatitis B. He is also actively performing cutting edge research on novel markers for hepatitis B infection and occult hepatitis B infection.

With all these international academic and professional achievements, Professor Yuen is an invited member serving as key opinion leader for several international coalition committees on hepatitis B disease.

Prof. Glenn Bonney

A/Prof Glenn Kunnath Bonney is the Director of Research, Department of Surgery at National University Hospital and the Director of SurgiCAL ProtEomics Laboratory, National University of Singapore. He attained his undergraduate medical degree in 2002 (MB ChB) from the University of Leeds, United Kingdom. Having completed Basic Surgical Training he was awarded Membership of the Royal College of Surgeons of England (MRCS) in 2006, he undertook a postgraduate research degree at Cancer Research UK to identify markers in bile for malignancy of the liver, while continuing clinical work at the Hepatobiliary and Transplantation Unit at St James’ University Hospital, Leeds. His proteomic based research culminated in a Doctorate of Medicine (MD) in 2008.

Having obtained a National Training Number, he subsequently undertook Higher Surgical Training in Birmingham, doing his specialist training at the University Hospitals of Birmingham, one of the largest liver transplant, liver and pancreas resection units in Europe. He became a Fellow of the Royal College of Surgeons of England in 2014.

He has numerous publications, presentations and invited lectures in liver transplantation, hepatocellular carcinoma, colorectal liver metastasis and pancreas cancer. With this experience, he was awarded a grant by the Royal College of Surgeons of England to pursue a 1 year fellowship for the investigation of the molecular biology of Hepatocellular Carcinoma at the National University Hospital Singapore (2013/14). On returning to the UK, he completed his surgical training and following a period as a Hepatobiliary and Transplant Surgeon, he returned to the National University Hospital Singapore.

A/Prof Bonney’s primary interest is in surgery for primary and secondary malignancies of the liver, pancreas and gallbladder, donor/recipient matching for liver transplantation and extending donor criteria. His clinical research has resulted in him receiving the Presidential Award of the International Hepatopancreaticobiliary Association (Seoul 2014).

Prof. Pei-Jer Chen

Graduate Institute of Clinical Medicine, National Taiwan University and Hospital.
No 7 Chung-Shan South Road,
Taipei, Taiwan

Professor Chen was appointed Director of the Hepatitis Research Center at the National Taiwan University Hospital in Taipei in 2001-2003, and now the faculty for Graduate Institute of Clinical Medicine, National Taiwan University. He was the President of Taiwan Association for Study of the Liver (TASL) from 2012 to 2013. He served as the President of Taiwan Society of Virology from 2016-2018.

His research interests focus on the molecular virology and immunology of hepatitis viruses, and the genetic and genomic study of hepatocellular carcinoma. Professor Chen’s clinical research covers the natural history of chronic viral hepatitis and hepatocellular carcinoma, and also explores and conducts new therapies and trials for both diseases. He has published over 630 articles in the areas of hepatitis and hepatocellular carcinoma.

He serves in the Editorial Board of Gastroenterology between 2017-2019. From 2001 to 2006 and then 2010-2011, was a member of the editorial board of the journal Hepatology and is reappointed from 2019-2021. In 2000, Professor Chen was awarded the International Research Scholar in Infectious Diseases by the Howard Hughes Medical Institute for a period of five years. He has been elected into Academia Sinica in year 2006, and become the TAWS member in year 2011.

Prof. Ann-Lii Cheng

Professor Ann-Lii Cheng is a Distinguish Professor at the National Taiwan University and Emeritus Superintendent of the National Taiwan University Cancer Centre. He remains an attending physician in the Department of Onctology and Internal Medicine, National Taiwan University Hospital.

He has contributed significantly to the basic knowledge and clinical application of molecular targeted therapy and immunotherapy in hepatocellular carcinoma (HCC). Living in the part of the world plagued by HCC, Prof. Cheng has devoted his career to substantiating a solution. Since 2004, he has been involved in the development of sorafenib and lenvatinib, two pivotal drugs in the first-line treatment of HCC, and recently the discovery of a new regimen, atezolizumab plus bevacizumab, which is considered an epoch-making breakthrough in this field. His research team at National Taiwan University has been recognized as one of the most prominent translational research groups in exploring the frontier of HCC treatment.

Prof. Toh Han Chong

Dr Toh is Senior Consultant and former Head at the Department of Medical Oncology and now Deputy Medical Director (Strategic Partnerships), National Cancer Centre, Singapore. He graduated from the University of London, UK with an intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. Dr Toh is also alumni at the Harvard Business School. He is currently the vice-chairman of the Oncology Academic Clinical Program (ACP) for Education.

He is a recipient of the National Clinician Scientist Award for his pioneering work in cell therapy for cancer. He conducted the first cancer vaccine and T cell therapy clinical trials in Singapore, and continues to work actively in the field of cancer immunotherapy, immunology and inflammation. He also had a strong interest in drug development for gastrointestinal cancers including colon and liver cancer. Dr Toh is an Associate Professor and College Master at the Duke-NUS Medical School. He is also an adjunct Principal Investigator at the Institute of Molecular and Cell Biology, A*STAR. He was a council member in the Singapore Medical Association and the Singapore College of Physicians.

Prof. Hashem el-Serag

Hashem B. El-Serag, M.D., M.P.H.
Margaret M. and Albert B. Alkek Professor and Chair Department of Medicine
Baylor College of Medicine, Houston, Texas

Dr. El-Serag obtained his medical degree from Al-Arab Medical University in Libya, completed his internship and residency in internal medicine (1995) at Greenwich Hospital, Yale University, Connecticut, and completed a fellowship in gastroenterology (1997) at the University of New Mexico, Albuquerque, New Mexico, where he also earned a master’s degree in public health (1998). In 1999, Dr. El-Serag joined the Michael E. DeBakey VA Medical Center and Baylor College of Medicine (BCM) in Houston, where he later became Chief of the Section of Gastroenterology & Hepatology (2007-2016). In 2017, he was appointed as Chair of the Department of Medicine at BCM.

Dr. El-Serag’s research focuses on the clinical epidemiology and outcomes of several digestive disorders, including Barrett’s esophagus, esophageal adenocarcinoma, hepatocellular carcinoma and hepatitis C. He has obtained >60 funded research grants including those from NIH, VA and Cancer Prevention Research Institute of Texas (CPRIT). He has >540 published papers to his credit including those published in New England Journal of Medicine, JAMA, Annals of Internal Medicine and Gastroenterology. His national leadership roles included Editor-in-Chief for Clinical Gastroenterology and Hepatology (2012-2017) and President of American Gastroenterological Association (2019). Dr. El-Serag’s has been selected into the American Society for Clinical Investigators (ASCI) and American Association of Physicians (AAP).

Dr. Asim Shabbir

Asst Prof. Asim Shabbir is a Senior Consultant with the Division of General Surgery (Upper Gastrointestinal Surgery) at the National University Hospital, Singapore. He is also Head of General Surgery at Alexandra Hospital.

He completed his basic and advance surgical training at NUH, Singapore. He was awarded fellowships from Royal College of Surgeons of Edinburgh and was accredited a surgical specialist by the Specialist accreditation board in 2007. In 2009, he did a clinical fellowship on Gastric cancer management with special interest in laparoscopic surgery for gastric cancer at the Seoul National University Hospital, South Korean. In 2010, he trained at Eda Hospital, I Shou University Kaohsiung, Taiwan in Bariatric and Metabolic surgery and was awarded as Fellowship.

Asst Prof. Asim’s specialty is general surgery and his special interests are upper gastrointestinal surgery, bariatric & metabolic surgery, advance endoscopy and laparoscopic surgery. He has been active in international as well as local meeting of his interest. His research interest includes obesity, surgery for type 2 diabetes and gastric cancer. He won the Best free paper award for his presentation “Laparoscopic Roux-en-Y Gastric Bypass for the Treatment of Type II Diabetes Mellitus in Chinese Patients with Body 25-35kg/m2at Asia Pacific metabolic bariatric surgical society meeting 2010. He has published in reputed journals in his field of interest.

Prof. Jia Jidong

Jidong Jia is currently Professor of Medicine, Director of Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Professor Jia is the immediate past President of the International Association for the Study of the Liver(IASL), past President of Asian Pacific Association for the Study of the Liver (APASL 2009-2010) and Chinese Society of Hepatology (CSH 2006-2012). Professor Jia also serves as Associate Editor for Hepatology International and served as Associate Editor for Journal of Gastroenterology & Hepatology and Liver International. As a hepatologist, his clinical interests include viral, cholestatic/autoimmune and genetic liver diseases. His research work focuses mainly on cellular and molecular biology of the extracellular matrix of the liver and the pathogenesis and therapeutic study of experimental liver fibrosis. In addition, Dr. Jia has been PI or sub-PI for many clinical trials and also heavily engaged in the teaching of clinical research methodology for residents and fellows in clinical medicine. He has authored or co-authored more than one hundred papers published in national and international journals including Gastroenterology, Gut, Hepatology, and Journal of Hepatology.

Dr. Jonathan Lee

Consultant, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital

Dr. Alfred Kow

A/Prof Alfred Kow is a practicing surgeon at the Division of Hepatobiliary & Pancreatic Surgery, NUH.

A/Prof Kow obtained his Master of Medicine (Surgery), Master of the Royal College of Surgeons of Edinburgh and Ireland diplomas in 2005 and subsequently, completed his advanced surgical training in Tan Tock Seng Hospital. In 2009, he obtained his Fellowship of the Royal College of Surgeons of Edinburgh (General Surgery) in Hong Kong. He was also accorded Specialist accreditation in General Surgery by Ministry of Health, Singapore in the same year.

He received the funding from National University Health System in 2010 to undergo fellowship training in living donor liver transplantation (LDLT) and hepatobiliary & pancreatic surgical oncology in Samsung Medical Center & Samsung Cancer Center, Sungkyunkwan University School of Medicine in Seoul, South Korea. During his one-year stay in Korea, he authored or co-authored 6 peer-reviewed journals.

He has also published numerous articles on pancreatic surgery, liver surgery and biliary surgery at peer reviewed journals and written a book chapter. A/Prof Kow is strongly interested in liver transplantation (both deceased donor and living donor) as well as minimally invasive (laparoscopic) surgery for hepatobiliary and pancreatic conditions.

In addition, A/Prof Kow has keen interest in research activities involving development of surgical techniques in HPB surgery and outcome of surgical treatment for HPB malignancies. The other areas that he is keen to research on are liver transplantation, peri-transplant management and outcome studies.

Furthermore, he is also actively developing research to help improve surgical education and training for both undergraduate and postgraduate setting. Most of his research work on education aim to understand the art and science behind training junior doctors to be excellent surgeons for the future. He has previously won grants to study the use of mobile applications in teaching patient safety in surgery.

Dr. Raghav Sundar

Dr. Raghav Sundar is a clinician-scientist specialising in gastrointestinal oncology. He is a consultant medical oncologist at the National University Cancer Institute, Singapore, treating patients with gastrointestinal malignancies including colorectal, gastric and hepatobiliary malignancies. He also specialises in experimental therapeutics and early phase clinical trials, and is a part of the Phase 1 clinical trials team. He underwent fellowship training at the Drug Development Unit, Royal Marsden Hospital, UK. His research interest is in genomics of gastric cancer. He studies the interaction between the tumor epigenome and the immune microenvironment. His work has identified predictive biomarkers of systemic therapy in gastric cancer as well as potential therapeutic targets. His studies incorporate contemporary technology such as spatial transcriptomics and machine-learning. Another area of research interest in chemotherapy induced peripheral neuropathy. As a translational clinician-scientist his works arches across several domains, collaborating with engineers, bioinformaticians, laboratory scientists, pharmaceutical and industry partners. He has published over 50 manuscripts, in high impact journals such as Cancer Discovery and Gut and secured over $4 million in grant funding to date.

Prof. Teerha Piratvisuth

Associate Professor of Medicine, Prince Songkla University, Hat Yai, Thailand and Director of NKC Institute of Gastroenterology and Hepatology Songklanagarind Hospital, Hat Yai.

Prof. Teerha Piratvisuth is affiliated to NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, where he is currently working as Associate Professor. He has authored and co-authored several national and international publications and also working as a reviewer for reputed professional journals. He has an active association with different societies and academies around the world. Prof. Teerha Piratvisuth major research interest involves NKC Institute of Gastroenterology and Hepatology.

Dr. James Fung

James Fung is a Consultant at the Department of Medicine, and the Transplant Hepatologist at the Liver Transplant Centre, Queen Mary Hospital, Hong Kong. He graduated from the University of Auckland School of Medicine in 1997. In 2011 he attained his Doctor of Medicine studying non-invasive assessment of liver fibrosis. He has published widely and is a regular reviewer for major gastroenterology journals and a regular speaker. His main research interest includes viral hepatitis, liver fibrosis, advanced liver disease, hepatocellular carcinoma, and liver transplantation.

Prof. Guadalupe Garcia Tsao

Guadalupe Garcia-Tsao, M.D., professor of medicine (digestive diseases), is the new president-elect of the American Association for the Study of Liver Diseases. Garcia-Tsao is a staff physician at the VA Connecticut Healthcare System, where she is chief of the Section of Digestive Diseases and program director of the Hepatitis C Resource Center. She is also director of the Clinical Core of the NIH-funded Liver Center at Yale. Garcia-Tsao earned her medical degree from the Universidad Nacional Autónoma de México and completed her internal medicine residency and gastroenterology fellowship at the Instituto Nacional de la Nutrición in Mexico City. She completed her training in hepatology at Yale and joined the faculty in 1989.

Prof. Rajender Reddy

Dr. Reddy is the Ruimy Family President’s Distinguished Professor of Medicine and Professor of Medicine in Surgery in the Division of Gastroenterology/Hepatology at the University of Pennsylvania in Philadelphia, Pennsylvania. He is the Director of Hepatology, Medical Director of Liver Transplantation, and the Director of the Viral Hepatitis Center.

Dr. Reddy received his medical education from Osmania Medical College in Hyderabad, India. He then completed a residency in internal medicine at NewYork Medical College Hospitals, a fellowship in Gastroenterology at East Tennessee State University College of Medicine, and a fellowship in Hepatology at the University Of Miami School Of Medicine. Subsequently he joined the faculty at the University of Miami and in October 2001, Dr.Reddy moved to the University of Pennsylvania to the current position.

A Fellow of the American College of Physicians, American College of Gastroenterology, and the Royal College of Physicians (UK), Dr. Reddy is also a Fellow and Councilor-at-Large of the American Association for the Study of Liver Diseases. He has held several Visiting Professorships at Medical Schools throughout the World. He has trained several fellows and mentored numerous research assistants throughout his career.

Dr. Reddy has authored or co-authored over 350 peer-reviewed papers on a spectrum of hepatobiliary topics that include liver transplantation, chronic C viral hepatitis, HIV and the liver, and hepatocellular carcinoma. In addition, he has edited and contributed to several text books, and has participated in numerous scientific presentations at National and International meetings. He serves on the editorial boards of prestigious journals such as Liver Transplantation, Hepatology, Liver International, and is an ad-hoc reviewer for several journals.

Dr. Reddy also has participated in a number of clinical trials that have advanced the understanding of the therapy of chronic viral hepatitis. He has been the recipient of both federal and non-federal funding for clinical research. His current research interests include areas of liver transplantation, viral hepatitis, and hepatocellular carcinoma.

Prof. Pietro Lampertico

Pietro Lampertico, MD, PhD, is an Associate Professor of Gastroenterology, Director of the Gastroenterology and Hepatology Division, and Head of the A.M. e A. Migliavacca Center for the Study of Liver Disease at the University of Milan in Italy. He graduated from the State University of Milan with degrees in medicine and surgery and performed postdoctoral research in the Department of Experimental Pathology at Tulane University in New Orleans, LA. Upon returning to Milan, he completed training in liver diseases and internal medicine. He received his PhD in clinical methodology from the University of Milan. Dr Lampertico’s clinical and research interests include viral hepatitis, metabolic liver disorders, autoimmune liver disorders, hepatocellular carcinoma, hepatic fibrosis, portal hypertension, fatty liver disease, liver transplantation, and alcoholism. He has special expertise in caring for patients with chronic cirrhosis due to untreated hepatitis B virus (HBV) infections, optimizing long-term outcomes for cirrhotic patients undergoing antiviral treatment, and managing antiviral resistance to oral nucleos(t)ide analogues. A well-published scholar, Dr Lampertico serves as a reviewer for numerous top-tier journals in his field, including Lancet, Gastroenterology, Hepatology, Gut, and the Journal of Hepatology. He is a member of the American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), the Italian Association of Liver Study (AISF), and the Italian Society of Gastroenterology (SIGE), among many other professional societies. He speaks frequently at international conferences about liver diseases, especially on the natural history of HBV and antiviral treatment, and is involved in national and international HBV clinical trials.

Prof. Patrick Marcellin

Patrick Marcellin is Professor of Hepatology at the University of Paris and Head of the Viral Hepatitis Research Unit in Hôpital Beaujon, Clichy. He earned his medical degree from the University of Paris and undertook postgraduate training in both internal medicine and gastroenterology-hepatology at the Assistance Publique-Hôpitaux de Paris. Professor Marcellin completed research fellowships in immunology (College of Physicians and Surgeons at Columbia University, New York City, USA) and virology (Institut Pasteur, Paris). He also holds a PhD in virology. Since 1984, he has been actively involved in laboratory and clinical research on viral hepatitis and liver diseases. His major focus has been on viral hepatitis therapy, and as such he has been the principal investigator on initial trials of first interferons and antivirals and on several pivotal studies investigating therapies for chronic hepatitis B and C. He published more than 500 articles in the best journals (NEJM, Lancet, Gastroenterology, Hepatology, J Hepatol…). Professor Marcellin was a member of the Scientific Committee of EASL and organised the EASL Consensus Conference on Hepatitis C in 1999 and the EASL Consensus Conference on Hepatitis B in 2002. He was the Chairman of the panel on the 2009 EASL hepatitis B guidelines. He is the President of APHC that has organised the Annual Paris Hepatitis Conference (PHC) since 2004.

Dr. Daniel Huang

Dr. Daniel Q. Huang graduated from the Yong Loo Lin School of Medicine, National University of Singapore, and completed his postgraduate residency training in the National University Hospital. Presently, he is an Assistant Professor at the National University of Singapore and a transplant hepatologist at the National University Hospital, Singapore.

Dr. Huang’s research interest is in early detection and prevention of hepatocellular carcinoma in the setting of non-alcoholic fatty liver disease and viral hepatitis. He conducts clinical and translational research in these areas and has first or corresponding author publications in journals such as Clinical Gastroenterology and Hepatology, Cellular and Molecular Gastroenterology and Hepatology, Alimentary Pharmacology & Therapeutics, Nature Reviews Gastroenterology & Hepatology and The Lancet Oncology. Dr Huang is currently leading several multinational studies in the field of liver cancer and viral hepatitis.

Dr. Kamarjit Singh Mangat

Dr Kamarjit qualified in 1993, UK, then completed Basic Surgical Training in UK and Australia, obtaining Fellowship of Royal College of Surgeons, London. Interest in Interventional Radiology led to Radiology training, Fellowship of the Royal College of Radiologists UK and a fellowship in Interventional Radiology. Specialist interest in Hepatobiliary Radiology led to a sabbatical at University of California, San Diego.

From 2005 to 2014 he was a Consultant Radiologist at Queen Elizabeth University Hospital Birmingham, UK working with the Liver Unit (one of the largest in the world), and also Birmingham Children’s Hospital. From 2010 to 2014 he was the Head of Radiology. In 2014 he was invited to lead liver radiology services at National University Hospital Singapore, and is currently a Senior Consultant Radiologist and Research Director for the Radiology Department.He has expertise in all forms of liver imaging and intervention, in particular TIPS, post-transplant intervention, biliary procedures, Budd-Chiari syndrome and minimally invasive treatment of tumours using ablation techniques, TACE and SIRT.

Dr. William Pirjamali

William received an MSc in Genetic Counseling from McGill University and has been working with Fulgent Genetics since 2017. He collaborates with clinicians and research partners all over the world to provide a broad portfolio of clinical genetic tests. Fulgent’s catalog of genetic tests covers a wide range of clinical subspecialties, and everything from prenatal testing to adult onset disorders, including liver disease. William has a special interest in Fulgent’s HelioLiver test, a novel multi-analyte blood test combining cell-free DNA methylation patterns and protein tumor markers to screen for hepatocellular carcinoma.

What our Preceptees have to say about the Preceptorship Programme in 2021

If you missed the Preceptorship Programme 2021 ONLINE or need a refresher, log in to this website to view the Trainer and Preceptee videos.

May, 2021

24

Programme
Evidence Based Medicine (EBM) and interpretation of the medical literature
Prof. Seng Gee Lim (Singapore) View Bio
Watch Video
Investigation of abnormal LFTs
Dr. Guan Huei Lee (Singapore) View Bio
Watch Video
Q & A
Case Presentations (1 hour) Faculty: Prof. Seng Gee Lim, Dr Guan Huei Lee

May, 2021

25

Programme
Is Cirrhosis Present? Diagnosis of Cirrhosis, Non-Invasive Markers and When to Biopsy
Dr. Daniel Huang (Singapore) View Bio
Watch Video
Overview of the Clinical Manifestations of Liver Cirrhosis
Dr. Mark Muthiah (Singapore) View Bio
Watch Video
Q & A
Case Presentations (1 hour) Faculty: Dr Daniel Huang, Dr Mark Muthiah

May, 2021

26

Programme
Benign Liver Diseases and How to Diagnose them: Fibrosing Nodular Hyperplasia, Hemangioma, Hepatic Adenomas and Hepatic Cysts
Dr. Prem Thurairajah (Singapore) View Bio
Watch Video
Overview of Biliary Diseases
Dr. Calvin Koh (Singapore) View Bio
Watch Video
Q & A
Case Presentations (1 hour) Faculty: Dr Prem Thurairajah, Dr Calvin Koh

PRECEPTEES ORAL PRESENTATION
PRECEPTORSHIP PROGRAMME 2021 ONLINE

This program is being supported by means of an unrestricted educational grant by Gilead Sciences Inc.

Menu